The National Pharmacy Association (NPA) and Royal Pharmaceutical Society (RPS) has been appointed as a core participant in the Covid-19 public inquiry.
The independent public inquiry has been set up to examine the UK's response to and the impact of the Covid-19 pandemic and learn lessons to shape preparations for
future pandemics. It is chaired by Baroness Heather Hallett, a former Court of Appeal judge.
The NPA and RPS will be part of Module 3, which covers the impact of Covid-19 on healthcare systems across the United Kingdom. The preliminary hearing for that
module takes place on Tuesday 28 February.
This will give the association an opportunity to make opening and closing statements, consider evidence provided to the Inquiry and propose questions to be asked by
the Inquiry of witnesses.
NPA chief executive, Mark Lyonette, said: "This is an historic opportunity to place on record the achievements of community pharmacy during the pandemic and to ensure
that the inquiry's recommendations are based in the practical realities faced by health workers such as our members.
Britain will start to roll out Merck's molnupiravir Covid-19 antiviral pill through a drug trial later this month, Susan Hopkins, chief medical adviser at the UK Health Security Agency said on Sunday (November 7).
Last week Britain became the first country in the world to approve the potentially game-changing Covid-19 antiviral pill, jointly developed by US-based Merck & Co Inc and Ridgeback Biotherapeutics.
The government said in October it had secured 480,000 courses of the Merck drug, as well as 250,000 courses of an antiviral pill developed by Pfizer Inc.
Asked about the molnupiravir approval, Hopkins told BBC television: "That is great news and it will start to be rolled out through a drug trial in the end of this month/the beginning of December."
Hopkins said all the trials so far had been done with the unvaccinated, so this would help understand how it will work in the wider vaccinated population.
Community pharmacies played a central role in the government's response to the Covid-19 pandemic, delivering more than 22 million jabs in the past 12 months.
Besides delivering millions of jabs, latest figures from NHS England and NHS Improvement (NHSE&I) revealed a 50 per cent increase in the number of pharmacies
delivering Covid boosters compared from October 2021 to January 2022.
NHSE&I released the data on Friday (January 14) to thank community pharmacy teams for their work during the crisis time.
Lauding the efforts made by community pharmacy teams during the pandemic, Pharmaceutical Services Negotiating Committee (PSNC) director of NHS Services Alastair Buxton said: "Just over a year ago we were fighting for Government recognition of the part community pharmacy could play in administering Covid vaccines, so a year later it is great to see the efforts of the pharmacy vaccination sites being praised by NHSE&I, with recognition of the significant role they have played in the overall programme.
More than 7,000 hospitalisations and deaths in the UK could have been averted in summer 2022 if people had received their recommended COVID-19 vaccine doses,
a new study published in The Lancet has revealed.
The largest ever study carried out in the UK found that between a third and a half of the UK population had not had the recommended number of COVID vaccinations and
boosters by summer 2022.
In Northern Ireland, nearly 50 per cent of the population were under-vaccinated, while the proportion of under-vaccinated people in England was 45.7 per cent,
34.2 per cent for Scotland and 32.8 per cent Wales.
Researchers from the Health Data Research UK (HDR UK) and the University of Edinburgh analysed the electronic health records of 67 million residents aged 5 and
older from across the four countries during June 1 to September 30 2022.
The General Pharmaceutical Council reiterated its stand on Covid-19 vaccination, saying, "Pharmacists and pharmacy technicians working in all settings across Great Britain should be vaccinated against Covid -19, unless they are medically exempt."
In a statement issued today (February 11), it strongly urged all pharmacyprofessionals, students and trainees to get fully vaccinated at the earliest.
This reiteration follows the government's announcement on January 31, 2022 that it would not proceed with Covid vaccination as a mandatory condition of deployment
for health and care staff providing CQC-regulated services in England.
The Council stated that clinical trials have proven the efficacy and safety of Covid vaccines and the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised their use in the UK.
The government has accepted the Joint Committee on Vaccination and Immunisation's (JCVI) advice for the autumn 2024 COVID-19 vaccination programme.
According to the JCVI, the following groups will be eligible for vaccination this autumn:
Individuals aged 65 and over
Residents of care homes for older adults
Those aged 6 months and older in clinical risk groups
Minister for Public Health and Prevention, Andrew Gwynne, emphasised the importance of protecting vulnerable populations from COVID-19 and reducing pressure on
the NHS.
He said: "We are committed to protecting those most vulnerable from COVID and have accepted the independent advice from the JCVI for the autumn 2024 vaccination
programme."
"I encourage anyone invited for a vaccine to get one as soon as possible to protect yourself and reduce pressure on the NHS during winter, helping to cut waiting
times and get the health service back on its feet."
The world has never been in a better position to end the Covid-19 pandemic, the head of the World Health Organization said on September 14, his most optimistic
outlook yet on the years-long health crisis which has killed over six million people.
"We are not there yet. But the end is in sight," WHO Director-General Tedros Adhanom Ghebreyesus told reporters at a virtual press conference.
That was the most upbeat assessment from the UN agency since it declared an international emergency in January 2020 and started describing Covid-19 as a pandemic
three months later.
The virus, which emerged in China in late 2019, has killed nearly 6.5 million people and infected 606 million, roiling global economies and overwhelming healthcare
systems.
The rollout of vaccines and therapies have helped to stem deaths and hospitalisations, and the Omicron variant which emerged late last year causes less severe
disease. Deaths from Covid-19 last week were the lowest since March 2020, the U.N. agency reported.
Britain has approved Novavax's Covid-19 vaccine for use in those 18 years of age and older, the country's medicines regulator said on Thursday (February 3), bringing a fifth coronavirus shot to its roster amidst the rapid spread of the Omicron variant.
The vaccine, Nuvaxovid, was approved as a first and second dose as it met the required safety, quality and effectiveness standards, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) said in a statement.
The British approval for Nuvaxovid comes days after the drugmaker filed for US authorisation of the vaccine following months of struggles with development and manufacturing problems, and follows a German backing earlier in the day.
"We are continuing our vital safety work in monitoring the use of all Covid-19 vaccines, to ensure that their benefits in protecting people against Covid-19 disease continue to outweigh any risks," MHRA chief executive June Raine said.
Prime minister Boris Johnson announced on Wednesday (January 19) that restrictions re-imposed in England last month would be lifted by from next Thursday (January 27).
In the latest development, the government has decided to end the guidance on working from home, asking employers to make adequate arrangements to return safely to work.
From the start of next Thursday, mandatory certification based on vaccines and tests will end, however, organisations can still choose to use the NHS Covid Pass voluntarily.
Besides, the legal mandate to wear face masks will go away from next week.
Making a statement to the House of Commons on Covid-19, he said that infection levels are falling in England mainly because of the country's "extraordinary booster campaign".
He noted more than 36 million Covid-19 booster jabs had been delivered, with over 90 percent of over-60s now given a third dose.
"Our scientists believe it is likely that the Omicron wave has now peaked nationally," Johnson added, while cautioning "the pandemic is not over".
"I encourage everyone across the country to continue with all the cautious behaviours that we know help to keep each everybody safe."
The NHS on Sunday (January 30) expanded its Covid-19 vaccination programme to include vulnerable children aged five to 11 years.
Eligible children include those with diabetes, immunosuppression, learning disabilities, and other conditions as outlined by the UK Health Security Agency in the Green Book.
Besides, children living with someone immunosuppressed will be eligible to get the first dose of the Covid vaccine in line with advice issued by the Joint Committee on Vaccination and Immunisation (JCVI).
According to the NHS there are around 500,000 eligible children in the latest cohort.
GP and deputy lead for NHS vaccination programme Dr Nikki Kanani, said: "We know vaccines give significant protection against severe illness from Covid - including the omicron variant, so it is important that our youngest and most at-risk get protected.
The Joint Committee on Vaccination and Immunisation (JCVI) on Thursday (May 19) said that an anticipated autumn Covid booster campaign would be aimed at
people aged over 65, care home residents, frontline health and social care workers and all adults in a clinical risk group.
The UK is offering a spring booster to the over-75s, care home residents and immunosuppressed people, and ministers have spoken openly of plans for a further
booster campaign in the autumn.
In interim advice, the JCVI stopped short of recommending another shot for all adults, though said the advice would be reviewed and updated.
"The JCVI's current view is that in autumn 2022, a Covid-19 vaccine should be offered to: residents in a care home for older adults and staff; frontline health
and social care workers; all those 65 years of age and over; and adults aged 16 to 64 years who are in a clinical risk group," the UK Health Security Agency said
in a statement.
Prime minister Boris Johnson, who was fiercely criticised for his handling of the early stages of the pandemic, lifted Covid restrictions in England in February,
crediting Britain's quick initial vaccine rollout and the rollout of boosters with breaking the link between cases and deaths.
Alliance Healthcare UK has won a 'special achievement' award for its work during the Covid-19 pandemic at the Logistics UK Awards 2021.
The pharmaceutical wholesaler and it's subsidiary, Alloga UK - a specialist provider of supply chain solutions for healthcare manufacturers - received the 'Special Recognition Award for Outstanding Response to Covid' at an event held in central London on Thursday, December 9, 2021 - beating off stiff competition from a number of high profile challengers.
Alliance Healthcare's new managing director Marie Evans said: "I am delighted that our business and team of 6,000 colleagues have been recognised at this level for our contribution to the fight against Covid-19. Our main aim over this unprecedented period is to support the NHS, pharmacy and all UK patients, and this award is true recognition for all of that hard work and dedication."
The special award category was open to an individual or organization that demonstrated an outstanding response to the pandemic in 2020 within the logistics sector and included seven other nominees including the likes of National Highways, Hermes UK and Yodel.
Community pharmacy is at the heart of one of the most ambitious clinical trials ever undertaken by the UK's primary care network, says senior academic pharmacist
Professor Mahendra Patel.
The PANORAMIC trial has been designed to rapidly evaluate several antiviral treatments over time that could help people at high risk of Covid-19 recover sooner,
prevent the need for hospital admission and so ease the burden on the NHS.
The Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC) is a national priority trial led by Oxford University's
Primary Care Clinical Trials Unit.
Lead investigators say the study will enable early and rapid testing of novel antiviral agents and help repurpose existing drugs against Covid-19. As soon as the trial is set up for delivery, it will be open to eligible participants from across the UK.
Prof Patel, a key member of the trial's core team, said: "I'm really excited with this news and also by the prospect that there is a huge potential for pharmacy teams to help play a vital role in supporting this highly ambitious trial, as they have with the PRINCIPLE trial, now the world's largest community based clinical trial for Covid19."
The National Pharmacy Association (NPA) views the COVID vaccination programme as broadly successful, largely due to the efforts of healthcare workers and
volunteers.
However, it cited some areas that could be improved, notably the early involvement of community pharmacies in planning, operational challenges, and recognising
the role of community pharmacy in addressing vaccine hesitancy and inequalities.
Submitting its evidence to the Covid-19 Inquiry, the NPA highlighted that the community pharmacy should have been consulted and involved earlier in the planning
process, considering their two years of experience and expertise in administering annual influenza vaccination programs and the reach and resources of the 14,000
community pharmacies across the UK.
"Instead, community pharmacy was initially given a gap in service role, which failed to fully utilize their experience, expertise and resource," Lawyer Brian
Stanton told the Inquiry on behalf of the NPA during the Module 4 Preliminary Hearing on 22 May.
As the government today (November 15) announced plans to expand Britain's booster programme for Covid-19 vaccinations to cover all adults aged over 40, NHS Confederation welcomed the move.
The announcement follows the Joint Committee on Vaccination and Immunisation (JCVI) statement that all healthy adults aged 40-49 should be offered a booster, six
months after their second dose, and that 16 and 17 year olds should be invited to have a second dose.
Accepting the JCVI's advice, health and social care secretary Sajid Javid said: "All 4 parts of the UK intend to follow the JCVI's advice.
"We know immunity to Covid-19 begins to wane after 6 months and new data published today shows a third dose boosts protection against symptomatic infection to more than 90% - this highlights just how important it is that everyone eligible gets their top-up jabs as soon as possible."
It is not sustainable to give Covid-19 booster shots every three to six in the long term, Britain's chief scientific adviser said on Tuesday (January 4), even though the booster rollout is needed in the short term to combat the Omicron variant.
"It would be a situation that isn't tenable to say everyone's going to need to be having another vaccine every three or six months.
"That's not the long-term view of where this goes to," Patrick Vallance said at a news conference, adding that annual booster shots against Covid-19 might be necessary, similar to flu shots.
Community pharmacies saved nearly 20,000 lives up to autumn 2021 by vaccinating people against the Covid-19, the National Pharmacy Association said based on a National Audit Office (NAO) report released on Friday (February 25).
The report, having taken evidence from the NPA, highlighted that community pharmacies and GPs performed far beyond expectations in delivering the Covid-19 vaccine, as 71 per cent of jabs were administered by both healthcare providers till October-end, against an initial assumption of 56 per cent.
The report cited UK Health Security Agency figures, which estimated that the programme overall prevented up to 128,000 deaths and 262,000 hospitalisations by September 24 and September 19, respectively.
The estimated number is considerably higher, given the pivotal role played by pharmacies in this winter's phase of the vaccination programme, the NPA stated.
As the deadline for the frontline healthcare workers to get fully vaccinated approaches, tens of thousands of NHS staff who have not yet taken the Covid-19
vaccine face termination in just a fortnight.
Although it is estimated that the majority of NHS staff have been fully jabbed, health and social care providers in England will soon be needed to ensure that all those working in areas regulated by the Care Quality Commission (CQC), are fully vaccinated against Covid-19 before the April 1, 2022.
Those who are exempted from taking the vaccination do not fall under this purview.
According to the NHS England guidance around Vaccination as a Condition of Deployment (VCOD) for healthcare workers, all frontline staff must have had both the doses by April 1, meaning that by February 3 the first must have been administered and the second by March 31.
All unvaccinated frontline workers will be called into formal meetings from February 4 and given a warning of dismissal. Notices will then be issued from that day, with March 31 marking the end of the notice period
Britain has started counting possible Covid-19 reinfections in its daily coronavirus data, changing its approach to reflect the increased number of people
catching the disease for a second time as the Omicron variant predominates.
The UK Health Security Agency (UKHSA) added around 840,000 cases to the cumulative total, taking it to 17.3 million coronavirus infections reported.
Britain's daily Covid statistics previously would only count people who had tested positive for the first time to avoid double-counting people who had received multiple positive test results for the same infection.
However, with variants such as Omicron leading to an increase in reinfections, the UKHSA said it would change its method to treat positive tests as separate infections if there was at least 90 days between test results. The change took effect on Monday (January 31).
"Reinfection remained at very low levels until the start of the Omicron wave. It is right that our daily reporting processes reflect how the virus has changed," said Steven Riley, UKHSA's Director General of Data and Analytics.
Community pharmacies must be involved in future planning for public health emergencies, especially in cases where a quick response is needed such as the Covid-19 pandemic, a European-wide research has recommended.
The project, co-led by the University of Huddersfield professor Zaheer-Ud-Din Babar in medicines and healthcare, focuses on how community pharmacies dealt with the pandemic, covering 31 pharmacy interventions on Covid-19 in 32 countries in Europe.
The interventions include prevention, response, and recovery measures. It also covers improved access to medicines, expanded powers granted to pharmacies, rapid antigen testing, along with Covid-19 vaccination.
Community pharmacists in the US, Canada, and Australia have been engaged in pandemic prevention, preparedness, and response strategic guidance after the 2009 flu pandemic.
The aim of the research is to map the current reported practice and trends and review the pharmacies' intervention in Europe.